Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batiraxcept with PLD or Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT03639246Phase 1Completed
- Sponsor
- Aravive, Inc.
- Start
- Dec 2018
- Primary completion
- Jan 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of batiraxcept in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (6 arms), sponsored by Aravive, Inc. Primary endpoints: Incidence of Adverse Events at 6 months, Anti-tumor activity of AVB-S6-500 in combination with PLD at 18 months and 1 more. Started Dec 2018; status: completed.
02
Drugs
batiraxcept
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03639246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639246.